FDA seeks more information on Schering-Plough's Saphris

01/14/2009 | Star-Ledger (Newark, N.J.), The · Forbes

U.S. regulators requested more data from studies of Saphris, Schering-Plough's drug candidate for schizophrenia and bipolar disorder in adults. The FDA also made labeling recommendations but did not require additional trials. Schering said it will respond to the agency's concerns at the end of March.

View Full Article in:

Star-Ledger (Newark, N.J.), The · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations